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Abstract
Background. Nodular inflammatory cell infiltrates with
defined microarchitecture, i.e. tertiary lymphoid organs,
develop in the tubulointerstitium during chronic renal in-
flammation. CCR6 and the corresponding ligand CCL20
are involved in the formation of gut-associated lymphatic
tissue. We hypothesized that CCR6 might be involved in
the formation of nodular infiltrates in the kidney.
Methods. CCR6- and CD20-positive B cells were localized
in renal biopsies with IgA nephropathy (n = 13), membra-
nous nephropathy (n = 12), crescentic glomerulonephritis
(cGN, n = 11) and chronic interstitial nephritis (n = 13),
and in pre-implantation biopsies as controls (n = 8). The
mRNA expression of CCR6 and the ligand CCL20 was
quantified by real-time RT–PCR in 51 renal biopsies of
the same disease entities.
Results. In the pre-transplant biopsies, CCR6 was ex-
pressed by endothelial cells of peritubular and glomerular
capillaries. In patients with glomerulonephritis, infiltrating
cells were positive particularly in areas of nodular inflam-
matory cell accumulations. A major part of the CCR6-
positive cells were CD20-positive B cells, but a part of the
CD3-positive T cells were also found to be positive. The
constitutive expression of CCR6 on the endothelium of
glomerular capillaries was lost in biopsies with progressive
injury. Tubular epithelial cells expressed CCR6 in inflamed
kidneys, most commonly on the basolateral side.
Conclusions. CCR6 and the corresponding ligand CCL20
might therefore be involved in the recruitment of T and B
cells to organized nodular infiltrates in chronic renal in-
flammation. The functional role of endothelial CCR6
needs to be evaluated in further studies.
Keywords: B cells; CCL20; CCR6; chemokine receptor;
glomerulonephritis
Introduction
Lymphocytes, macrophages and dendritic cells accumulate
in the tubulointerstitium of the human kidney during pro-
gressive diseases [1–3]. The numbers of interstitial infiltrat-
ing T cells and macrophages correlate with renal function at
the time of biopsy [2,4]. In addition, to diffuse infiltrates,
leucocytes form nodular structures in about one-third
of the biopsies with chronic diseases [3,5]. These structures
are called tertiary lymphoid organs (TLOs), and the
functional role of TLOs in the kidney is under intense
investigation [6–8].
Chemokines are members of a large family of chemotac-
tic cytokines, which orchestrate the recruitment of inflam-
matory cell subsets under homeostatic and pathological
condition [9]. Expression and presentation of chemokines
in particular microenvironments are involved in the forma-
tion of lymphoid tissue as well as in chronic renal inflam-
mation [10–12]. The chemokine receptor CCR6 signals
after binding the chemokine CCL20, which is the only
known ligand for this receptor so far [13,14]. CCR6 is ac-
quired during B-cell maturation and is expressed by all
bone marrow, and peripheral blood-derived naive and
memory B cells [15]. CCR6 expression has been shown
in memory T cells, regulatory T cells, and IL-17-producing
CD4-positive T cells (a distinct subset of cells now re-
ferred to as Th17 cells) [16–19]. CCR6 is also expressed
on a subset of dendritic cells [17,20,21].
CCR6-positive B cells play an important role in the for-
mation of gut-associated lymphatic tissue, i.e. Peyer’s
patches and isolated lymphoid follicles [22]. The forma-
tion of TLOs during chronic inflammation might in part
be a recapitulation of the embryonic formation of second-
ary lymphoid organs [5]. Therefore, we hypothesized that
CCR6 might be involved in the formation of nodular infil-
trates in chronic renal inflammation. Therefore, we studied
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the expression of CCR6 and the ligand CCL20 in the most
common forms of human glomerulonephritis, as a pre-
requisite for further functional studies.
Materials and methods
Study population
Renal biopsies were formalin-fixed, and paraffin-embedded following
routine protocols. The diagnosis was based on light microscopy, immuno-
histochemistry and electron microscopy. Archival sections were used for
the current study from patients with crescentic glomerulonephritis (cGN,
n = 11), IgA nephropathy (n = 13), membranous nephropathy (n = 12)
and chronic interstitial nephritis (n = 13). Allograft biopsies taken before
implantation served as controls (n = 8).
Immunohistochemistry
Immunohistochemistry was performed as previously described [3,23]. In
brief, sections were dewaxed in xylene, rehydrated in a graded series of
ethanol, and incubated in 3% hydrogen peroxide. The Avidin/Biotin block-
ing Kit (Vector, Burlingame, CA, USA) was used to block endogenous bio-
tin. An autoclave oven (or microwave treatment) was used for heat-based
antigen retrieval in Antigen retrieval solution (Vector). Incubation with the
primary antibody was performed for 1 h. Incubation with biotinylated sec-
ondary antibodies (Vector) for 30 min was followed by the ABC reagent
(Vector). 3,3′Diaminobenzidine (DAB, Sigma, Taufkirchen, Germany)
with metal enhancement was used as a detection system. Two polyclonal
antibodies against CCR6 raised in two different rabbits were tested and re-
sulted in the same pattern (anti-human CCR6 by MBL International Cor-
poration, Woburn, MA, USA and Chemicon, Temecula, CA, USA). The
primary polyclonal antibody against CCR6 (Chemicon) was used in a di-
lution of 1:1000 in 10% non-fat dry milk on renal biopsies. Other anti-
bodies used were a monoclonal antibody against CD20 (clone L26,
DakoCytomation, Dako Deutschland, Hamburg, Germany), an anti-CD3
antibody (clone: CD3-12, rat anti-human, Serotec, Oxford, UK), and
an anti-CD34 antibody (Accurate Chemical and Scientific Corporation,
Westbury, NY, USA).
CD34 was stained on a total of nine biopsies on consecutive sec-
tions with CCR6 (four biopsies with chronic interstitial nephritis and five
controls).
The numbers of CD20- and CCR6-positive cells were scored semi-
quantitatively: 0, no infiltrating cells; 1, scattered positive infiltrating cells
between tubules; 2, accumulations of several infiltrating cells between
tubules; and 3, nodular appearance of the infiltrates by an observer blinded
to the disease entities.
Immunofluorescence
Double-labelling immunofluorescence was performed as described pre-
viously [3]. As secondary reagents, biotinylated antibodies (Vector),
Streptavidin/FITC complex (Vector), Cy3-labelled anti-rat antibody (Jack-
son Immunoresearch Laboratories Inc., West Grove, PA, USA), and Texas
red- and FITC-labelled anti-mouse IgG (Vector) were used.
Real-time RT–PCR
To quantify the mRNA expression of CCL20 and CCR6, we used real-time
RT–PCR as described [24]. The biopsies were from patients with cGN (n =
8), IgA nephropathy (n = 14), membranous nephropathy (n = 20) and allo-
graft biopsies taken before implantation served as controls (n = 9). The
renal biopsies were obtained from a multicentre renal biopsy bank (the
European Renal cDNA Bank, ERCB). Informed consent was obtained
before renal biopsies were performed. The microdissected tubulointersti-
tial compartments were used.
Real-time RT–PCR was performed on a TaqMan ABI 7700 Sequence
Detection System (Applied Biosystems, Darmstadt, Germany) using heat-
activated TaqDNA polymerase (Amplitaq Gold, Applied Biosystems).
Quantification of the given templates was performed according to the
standard curve method. Commercially available pre-developed TaqMan re-
agents were used for the target genes CCR6 (NM_031409) and CCL20
(NM_004591) (all from Applied Biosystems), and two endogenous control
genes (18S rRNA, GAPDH; Applied Biosystems). The normalization to
the two reference genes (housekeeper genes) gave comparable results.
The data shown in the text and figures are normalized to GAPDH.
All measurements were performed in duplicates. Controls consisting
of bidistilled H20 were negative in all runs. The samples used for the
Fig. 1. Establishment of the anti-CCR6 antibody and expression in normal human kidney. Immunohistochemistry was performed on an allograft
nephrectomy (A–C), and a pre-transplant biopsy (D and E) with a polyclonal antibody against CCR6 (B, D and E, Chemicon), a non-immune
rabbit serum (A), and after pre-absorption of the antiserum with the peptide (C, original ×250 D, E, original ×200 in A–C). The negative controls
performed with non-immune rabbit serum (A) and pre-absorption with the peptide used for the induction of the antiserum did not demonstrate a positive
colour product (C). Prominent signal of a nodular infiltrate in the allograft nephrectomy (B). In the well-preserved pre-transplant biopsies, a positive
signal was present on endothelial cells of glomerular capillaries (arrowheads, D) and peritubular capillaries (E, arrows).
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mRNA analysis were from a different cohort than the biopsies used for
immunohistochemistry.
Quantification and statistical analysis
The semi-quantitative scores for the interstitial CCR6-positive cells and
the percentage of CCR6 staining per glomerular area were evaluated by
observers blinded to the diagnosis. For the comparison of medians, the
non-parametric Kruskal–Wallis test and Dunn’s multiple comparisons test
were used. Spearman rank correlations were performed for the correla-
tions with clinical and morphological data (InStat® software, version
3.05, Intuitive Software for Science, San Diego, CA, USA). A P <0.05
was considered to be significant. Error bars illustrate standard error of the
mean (SEM).
Results
Description of the antibody and CCR6 expression in
pre-transplantation biopsies
For the establishment of the polyclonal anti-CCR6 anti-
serum, we used tissue sections from allograft nephrectomies
(Figure 1A–C). A reliable staining pattern was achieved
using a heat-based antigen retrieval. Expression of CCR6
was present on inflammatory cells and on endothelial cells
in these positive controls (Figure 1B). A second antiserum
against CCR6 resulted in the same pattern (not illustrated).
A non-immune rabbit serum did not result in a black colour
product (Figure 1A). Additionally, the pre-incubation with
the peptide used for the generation of the antibody com-
pletely abolished the signal (Figure 1C).
Double labelling of an allograft nephrectomy confirmed
that CD20-positive B cells formed a major part of the
CCR6-positive infiltrating cells (Figure 2A–C). CD3-
positive T cells represent additional CCR6-positive cells
(Figure 2D and E). Positivity of endothelial cells was con-
firmed in double-labelling studies with CD34, an endothe-
lial marker (Figure 2F–H).
Eight allograft biopsies taken before implantation were
used as controls (Figure 1D and E). These pre-transplantation
biopsies demonstrated well-preserved renal tissue, with vari-
able degrees of global glomerulosclerosis. Mild interstitial
Fig. 2. Double immunofluorescence for CCR6. Double Immunofluorescence was performed on tissue sections from an allograft nephrectomy. A–C.
Double labelling for CCR6 (A), CD20 (B) and the overlay in C illustrates the majority of this nodular aggregate being CCR6-positive B cells (arrows).
D and E illustrate an area with a high number of CD3/CCR6 double-positive cells (arrowhead). F–H illustrate CCR6-positive endothelial cells in a
glomerulus (F: CCR6, G: CD34, H: overlay, original ×400).
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infiltration was present surrounding sclerosed glomeruli,
a feature commonly found in ageing kidneys. These bi-
opsies therefore cannot be regarded as normal, as these
were exposed to cold ischaemia and the circumstances
of brain-dead of the deceased donors, but the morphology
demonstrated well-preserved tissue architecture.
In these biopsies, we found CCR6 to be expressed
by endothelial cells of glomerular and peritubular capil-
laries without prominent variation between the biopsies
(Figure 1D and E). Some circulating cells in the lumen
of open glomerular capillaries or peritubular capillaries
were found to be CCR6 positive, but these cells were rare.
Expression of CCR6 by tubular epithelial cells was only
occasionally found.
CCR6 expression in IgA nephropathy
Thirteen biopsies from patients with IgA nephropathy were
studied (Table 1). Expression of CCR6 was found on endo-
thelial cells of glomerular and peritubular capillaries. The
staining was less intense as compared with controls. Fur-
thermore, segmental to global loss of staining was present
in glomeruli (Figure 3A). Parietal epithelial cells were found
to be positive in a few glomeruli (Figure 3D). Tubular
epithelial cells showed weak basolateral staining with focal
distribution, particularly in tubules adjacent to sites of inter-
stitial inflammation (Figure 3C). Infiltrating CCR6-positive
Table 1. Basic clinical parameters of the patients included in the
immunohistochemistry cohort
Disease n
Age
(years)
Creatinine
(mg/dL)
Proteinuria
(g/24 h)
IgA N 13 37 (14–59) 1.5 (0.8–8.3) 1.5 (0–7)
Membranous N 12 45 (13–65) 1.1 (0.6–6.4) 7 (2.4–22)
cGN 11 63 (35–84) 3.8 (1.4–8.4) 0.4 (0.3–8)
c Int 13 44 (3–81) 4.8 (1.8–13) 0.6 (0.08–25)
Controls 8 27 (0–67) n.a. n.a.
Data are presented as median (range) except n. n.a., not available; N,
nephropathy; cGN, crescentic glomerulonephritis; c Int, chronic interstitial
nephritis.
Fig. 3. CCR6 expression in renal biopsies from patients with IgA nephropathy and membranous nephropathy. Immunohistochemistry was performed
on renal biopsies from patients with IgA nephropathy (A–D) and with membranous nephropathy (E–F) with a polyclonal antibody against CCR6 (A,
C–F) and a monoclonal antibody against CD20 (B; original ×100 in C–F, ×250 in A and B). Consecutive section in A and B demonstrates that only the
periphery of the CCR6-positive small nodular infiltrate consists of CD20-positive B cells. In C and D, the glomerular endothelial staining is lost.
Tubular CCR6 staining is illustrated in C (arrow). D demonstrates prominent CCR6-positive peri-glomerular infiltration and CC6 expression by
parietal epithelial cells (arrow). The staining pattern was similar in membranous nephropathy (E and F). Endothelial cells of arteries were rarely
found to be CCR6 positive.
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cells were found scattered throughout the cortex and at times
accumulated around the glomeruli. Nodular infiltrates were
present in 5 out of 13 biopsies. In small accumulations,
CD20-positive cells were outnumbered by CCR6-positive
cells not expressing CD20 (Figure 3A and B).
CCR6 in membranous nephropathy
Included were 12 biopsies from patients with membranous
nephropathy (Table 1). This was the group of patients with
the best preserved renal function. On intrinsic renal cells,
CCR6 was found to be expressed as in IgA nephropathy
(Figure 3E and F). Infiltrating CCR6-positive cells were
only found with diffuse distribution, and no formation of
nodular structures was present both in the CCR6 and
CD20 staining (Figure 3E and F).
CCR6 expression in cGN
Eleven biopsies from patients with crescentic glomerulo-
nephritis were included. All of these were pauci-immune
by immunohistochemistry. Therefore, no crescentic IgA
nephritis or anti-glomerular basement membrane diseases
were included in this group.
CCR6 was found to be expressed on glomerular endo-
thelial cells in preserved glomeruli, as described for nor-
mal controls, but segmental loss of positive staining was
common (Figure 4A). Tubular epithelial cells were
CCR6-positive in 8 out of 10 biopsies (Figure 4B). Oc-
casionally, intercalating cells of collecting ducts were
found to be positive (Figure 4B). An intensive accumulation
of CCR6-positive infiltrating cells was present in the
tubulointerstitium, but not in the glomeruli (Figure 4C and
E). Nodular infiltrates were almost uniformly CCR6 positive
(Figure 4C and D). These structures were commonly found
around the completely sclerotic glomeruli (Figure 4C and
D). On the other hand, scattered infiltrating cells were
only occasionally CCR6 positive. The distribution of
CCR6-positive cells matched only about half of the
CD20-positive cells (Figure 4C and D). In cGN, a high
number of macrophages are usually present in the glomeru-
lar tuft and in crescents [25]. The absence of CCR6 staining
on infiltrating cells in glomerular tufts and crescents indi-
cates that CCR6 is mainly expressed by lymphocytes (loca-
Fig. 4. CCR6 expression in biopsies with crescentic GN and chronic interstitial nephritis. Immunohistochemistry was performed on renal biopsies from
patients with cGN (A–D) and patients with chronic interstitial nephritis (E and F) with a polyclonal antibody against CCR6 (A–C, E and F) and with a
monoclonal antibody against CD20 (D, original ×250 in A–E, and ×400 in F). A segmental loss of the endothelial staining in the upper part of the
glomerulus is illustrated in A. Basal tubular expression of CCR6 is shown in B. A prominent accumulation of CCR6-positive cells was found around
globally sclerosed glomeruli, with CD20-positive cells being a major part of the infiltrate (C and D). In chronic interstitial nephritis, both interstitial
accumulation of CCR6-positive cells (E) and loss of endothelial CCR6 were present (F).
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lized in the tubulointerstitium), but not macrophages re-
cruited to glomeruli.
CCR6 in chronic interstitial nephritis
Included were 13 biopsies with chronic interstitial neph-
ritis (Table 1). The pattern of CCR6 expression was com-
parable to the glomerular diseases presented above.
Glomerular endothelial cells stained positive for CCR6,
but the staining intensity was weaker than in controls.
Occasionally, parietal epithelial cells demonstrated a
positive signal. In 10 out of 13 biopsies, tubular epithelial
cells were found to be focally CCR6-positive on basolateral
membranes of atrophic tubules of cortex and medulla
(Figure 4F). Inflammatory cells positive for CCR6 were
mainly scattered diffusely throughout the renal cortex
(Figure 4E). Additionally, in 9 out of 13 biopsies, nodular
structures were present, where the majority of these cells
were CCR6 positive (not illustrated).
In four biopsies, CD34 was stained in parallel with
CCR6. Complete loss of CD34 and CCR6 was present
in globally sclerosed glomeruli. Furthermore, some glom-
eruli demonstrated a less prominent CCR6 staining, and
also, CD34 was preserved.
Fig. 5. Comparison glomerular CCR6 expression between the glomerular diseases. Immunohistochemistry was performed with a polyclonal antibody
against CCR6 on renal biopsies before implantation (pre Tx control, A), with IgA nephropathy (B, IgA N.), with membranous nephropathy (membr. N.,
C) and with cGN (D, all original ×250). A weaker endothelial staining was found in all three glomerulopathies with segmental to global loss of the
staining pattern, even in preserved glomerular capillaries.
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Fig. 6. Morphometric quantification of glomerular CCR6 expression. Mean percentage of CCR6-positive colour product per glomerular area is
illustrated (*P < 0.05, **P < 0.01).
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Common pattern of CCR6 staining in different forms of
renal inflammation
The staining pattern for CCR6 was not associated with par-
ticular renal disease entities (Figure 5). The constitutive ex-
pression of CCR6 on endothelial cells on peritubular and
glomerular capillaries decreases in biopsies with chronic
glomerular injury as well as in chronic interstitial nephritis.
Particularly, in cGN, a prominent segmental to global loss of
CCR6 expression was present (Figure 6). As could be ex-
pected, globally sclerosed glomeruli demonstrated complete
loss of CCR6 staining. The loss of glomerular staining in
patients with chronic interstitial nephritis indicates that this
is not specific for the glomerular injury process, but rather
due to nephrosclerosis which is also present in chronic inter-
stitial nephritis (with globally sclerosed glomeruli). The
glomerular area of CCR6 expression did not correlate with
serum creatinine, proteinuria, or the overall percentage of
sclerosed glomeruli (not significant).
A semi-quantitative score was used to characterize the
tubulointerstitial infiltration by CD20- and CCR6-positive
cells (Table 2). There was an extremely significant correl-
ation between the CD20 and CCR6 scores (Spearman
r = 0.69, 95% confidence interval 0.51–0.81, P < 0.0001).
Furthermore, CCR6 scores were associated with serum
creatinine at the time of biopsy (Spearman r = 0.47,
95% confidence interval 0.17–0.69, P = 0.0027), but not
with proteinuria (not significant). The median creatinine
was significantly higher in the interstitial scores 1–3 vs
0, with a progressive increase from scores 1–3 (not illu-
strated). The interstitial CD20 scores were not associated
with serum creatinine and proteinuria (not significant),
consistent with previously published data [3].
A negative correlation was found between the percent-
age of CCR6 expression in glomeruli and the interstitial
CCR6 scores (Spearman r = −0.42, 95% confidence inter-
val from −0.64 to −0.13, P = 0.0049).
CCR6 and CCL20 mRNA expression in patients with
glomerulonephritis
The mRNA expression of CCL20 and the corresponding
receptor CCR6 was quantified by real-time RT–PCR in
the microdissected tubulointerstitium in renal biopsies
with IgA nephropathy, membranous nephropathy and
cGN (Table 3). All biopsies demonstrated a prominent ex-
pression of CCL20 mRNA (Figure 7A). Expression of
CCR6 was most prominently induced in biopsies with
IgA nephropathy and cGN (Figure 7B). A corresponding
expression was found for CCL20 and CCR6 mRNA, but
only the induction of the receptor reached the level of sig-
nificance (Figure 7A and B). The expression of CCL20
mRNA correlated significantly with the expression of
the corresponding receptor CCR6 mRNA (P < 0.05),
but not with serum creatinine or proteinuria at the time
of biopsy.
Discussion
The list of human diseases in which CCR6 plays a signifi-
cant role is rapidly growing and contains common ones
like colorectal carcinoma [26], Crohn’s disease, and
rheumatoid arthritis [27]. Particularly, the description of
CCR6 expression on Th17 cells sparked the recent interest
in this chemokine receptor [28]. The ligand receptor pair
CCL20/CCR6 is involved in the normal development of
gut-associated lymphatic tissue, as well as in the men-
tioned common human diseases [29].
In the mouse gut, the deficiency of CCR6 leads to
reduced sizes of Peyer’s patches with loss of B cells
and T cells, and particularly a reduction of regulatory
CD4-positive T cells [30]. M cells, a specialized cell type
within Peyer’s patches, are also reduced in number [31].
CCR6-deficient mice are protected from oral Yersinia ente-
rocolitica infection, which exploits M cells for infection
[31]. Isolated lymphoid follicles are organized lymphoid
structures in the gut in which B cells are the major CCR6-
positive population. The formation of these structures was
significantly disturbed due to a reduction of B-cell influx in
CCR6-deficient mice [22]. These studies highlight the role
of CCR6 in lymphogenesis of the gut. CCR6 has also re-
cently been documented on mouse regulatory T cells and
in IL-17-producing CD4-positive T cells. CCR6 deficiency
aggravated renal injury in mouse nephrotoxic nephritis and
increased mortality illustrating the recruitment of regulatory
T cells through CCR6 [32]. Future studies need to address
the expression of CCR6 by inflammatory subsets in the hu-
man kidney.
CCL20 can also be induced under inflammatory condi-
tions [29]. Therefore, we hypothesized that the formation
of tertiary lymphoid organs might in part be a recapitula-
tion of embryogenesis. We localized CCR6 in human kid-
Table 2. Morphological results of the study population
Disease n Interstitial CD20 scores Interstitial CCR6 scores
IgA N 13 1 (0–3) 1 (0–3)
Membranous N 12 1 (0–2)* vs cGN 1 (0–3)
cGN 11 2 (1–3)*** vs control 2 (1–3)* vs control
c Int 13 2 (1–3)** vs control 2 (1–3)** vs control
Controls 8 0 (0–1) 0 (0–1)
Data are presented as median (range) except n. n.a., not available; N,
nephropathy; cGN, crescentic glomerulonephritis; c Int, chronic interstitial
nephritis.
*P < 0.05.
**P < 0.01.
***P < 0.001.
Table 3. Basic clinical parameters of the patients included in the mRNA
expression cohort
Disease n
Age
(years)
Creatinine
(mg/dL)
Proteinuria
(g/24 h)
IgA N 14 52 (17–72) 2.3 (1.5–6.2) 3.0 (0.5–6.3)
Membranous N 20 55 (17–85) 1.0 (0.7–2) 4.7 (0.6–9.8)
cGN 8 53 (27–69) 1.3 (0.9–6.4) 0.7 (0.1–1.8)
Controls 9 56 (27–70) n.a. n.a.
Data are presented as median (range) except n. n.a., not available; N,
nephropathy; cGN, crescentic glomerulonephritis; c Int, chronic interstitial
nephritis.
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ney diseases in which the formation of tertiary lymphoid or-
gans has previously been described [3,33]. This is the first
detailed analysis on the expression of CCR6 in human renal
biopsies from patients with glomerular and tubulointerstitial
diseases. Consistent with our hypothesis, we found that a
prominent number of B cells and T cells were CCR6-positive
in the tubulointerstitium. The distribution of CCR6-positive
cells was interesting as these were mainly found at sites of
larger, nodular lymphocyte accumulations. Staining for
CD20-positive cells demonstrated that a major part (about
half) of the CD20-positive cells were also CCR6-positive.
The majority of the remaining cells are most likely T cells
(lymphocytes according to the morphology).
In contrast to the loss of CCR6 on glomerular endothelial
cells, we found an increase of interstitial CCL20 and CCR6
mRNA expression particularly in IgA nephropathy. There
was an inverse correlation between the glomerular expres-
sion of CCR6 and the tubulointerstitial scores. Therefore,
the interstitial expression is consistent with the immunohis-
tochemistry finding.
As previously described, T and B cells are present within
the tubulointerstitium in high numbers during chronic renal
inflammation, but not within the glomerular tuft [3,34]. This
mirrors the distribution of CCR6 infiltrating cells in renal
tissue. Furthermore, glomerular macrophages do not seem
to express CCR6 because CCR6-positive cells were not
present in this tissue compartment. In contrast to the high
number of CCR6-positive cells in TLOs, the diffuse intersti-
tial infiltrates were rarely CCR6 positive. This could be ex-
plained in two ways, either a particular recruitment of
CCR6-positive cells to tertiary lymphoid organs or an in-
duction of CCR6 in nodular infiltrates. This is the first che-
mokine receptor described in the human kidney which is
expressed both on B cells and T cells. Other chemokine re-
ceptors have been shown to be expressed on T cells (e.g.
CCR5 [34]) or on B cells (e.g. CXCR5 [3]). CCR6 might
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Fig. 7. Real-time expression of CCL20 (A) and CCR6 (B) in the tubulointerstitium of renal biopsies from patients with IgA nephropathy (IgA N.),
membranous nephropathy (membran. N.) and cGN. Allograft biopsies taken before implantation were used as controls (Pre Tx, *P < 0.05, **P < 0.01).
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therefore be involved in orchestrating a rendezvous between
T cells and B cells, particularly at sites of nodular infiltrates.
The only study on CCL20 and CCR6 in human kidneys
has been published byWoltman et al. [35]. In this study, the
authors described the expression of CCL20 by tubular epi-
thelial cells, and CCR6 by a subset of inflammatory cells in
rejecting allografts [35]. Particularly, CCR6was localized to
dendritic cells in rejecting renal allografts [35]. Our study is
the first addressing the expression in endogenous kidney
diseases.We could confirm the expression of CCR6 by den-
dritic cells in allograft nephrectomies (not illustrated).
The constitutive expression of CCR6 on endothelial
cells of glomerular and peritubular capillaries was an un-
expected finding. This expression was reduced during in-
flammation. Evidence for CCR6 expression on endothelial
cells has been provided for human umbilical vein endothe-
lial cells, saphenous vein endothelial cells, and dermal and
lung microvascular endothelial cells [36,37]. Expression of
CCR6 has been found to be induced on human umbilical
vein endothelial cells after infection with human herpes
virus 8 [38]. Induction of CCR6 on human umbilical vein
endothelial cells was also described after combined stimu-
lation with hepatocyte growth factor and vascular endothe-
lial growth factor (VEGF) [36]. Loss of CCR6 was present
in focal and global glomerulosclerosis. Due to limitations
in materials, we cannot at the moment exclude that there is
a regulation of CCR6 independent of endothelial cell loss.
This and the functional role of a constitutive expression of
CCR6 on renal endothelial cells remain to be evaluated.
Another ligand receptor pair, i.e. CXCL12/CXCR4, has
been shown to be involved in angiogenesis of the kidney
during development but also in neoangiogenesis in malig-
nant tumours [39,40]. Mechanisms involved in endothelial
biology might be the recruitment of endothelial stem cells
or a direct induction of migration/proliferation of endothe-
lial cells. Interactions between CXCR4 and CCL20 have
been shown to play a role in malignant diseases; therefore,
an interaction of these systems might be envisioned in the
renal vasculature [41].
In summary, we found CCR6 to be expressed by infiltra-
ting lymphocytes, both B cells and T cells, predominantly in
nodular accumulation and, to a lesser extent, in diffuse inter-
stitial infiltrates. Furthermore, there might be a role for
CCR6 on intrinsic renal cells particularly endothelial cells.
The functional evaluation will have to await further in vitro
studies and studies on CCR6mutant mice. These studies are
currently hampered as useful mouse models of tertiary
lymphoid organ formation in the kidney associated with
chronic inflammation wait to be established.
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Anti-C1q autoantibodies do not correlate with the occurrence or
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Abstract
Background. In systemic lupus erythematosus patients, a
strong association between the occurrence of antibodies
against complement C1q (anti-C1q) and lupus nephritis
can be observed. However, the predictive value of anti-
C1q titres for a renal flare remains to be determined. In-
creasing titres of anti-C1q before the occurrence of clinical
apparent nephritis might not only serve as a clinical param-
eter but also indicate a direct pathogenic mechanism of
anti-C1q.
Methods. The aim of this study was to analyse the occur-
rence of anti-C1q before the onset of experimental lupus
nephritis in MRL/MpJ +/+ mice and to correlate anti-C1q
titres with the type and severity of glomerulonephritis (GN)
developing at advanced age.
Results. As judged by a number of morphological and im-
munological analyses, GN in MRL/MpJ +/+ mice re-
sembled human lupus nephritis and occurred in variable
degrees of severity. We also observed an abundant and early
presence of anti-C1q. However, anti-C1q neither correlated
1220 C. Bigler et al.
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